Therapy of Acute Myeloid Leukemia

    January 2012 in “ InTech eBooks ”
    Jean El‐Cheikh, Roberto Crocchiolo
    TLDR Treating acute myeloid leukemia is challenging, especially in older adults, despite some advancements.
    Acute myeloid leukemia (AML) was the most common acute leukemia in adults, with less than one-third of patients being curable. Standard induction therapy typically included daunorubicin (DNR) and cytarabine, achieving complete remission (CR) rates of 60%-80% in young adults and 40%-60% in older adults. Studies showed that higher doses of DNR (90 mg/m²) improved CR rates and overall survival (OS) in younger patients, but not significantly in older patients. Liposomal formulations like CPX-351 reduced non-hematologic toxicities while maintaining efficacy. Despite advancements, treating refractory, relapsed, and elderly AML remained challenging, necessitating ongoing research into new regimens and targeted therapies.
    Discuss this study in the Community →